Physician profile
Gerald Dunham
NPI 1528173788
$1,061.60
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.96 · 2020: $358 · 2021: $255 · 2022: $154 · 2023: $136 · 2024: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $375.11 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $105.51 | 2020 | |
| Abbvie INC. | $101.04 | 2022-2024 | Durysta |
| Sun Pharmaceutical Industries INC. | $93.38 | 2019-2024 | Cequa |
| Bausch & Lomb Americas INC. | $83.05 | 2022-2024 | Vyzulta, Envista Mx60 Iol, Xiidra |
| Ocular Therapeutix, INC. | $74.40 | 2020-2024 | Dextenza |
| Novartis Pharmaceuticals Corporation | $53.31 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.71 | 2019-2021 | |
| Alcon Vision LLC | $29.47 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $28.85 | 2021 | |
| Oyster Point Pharma, INC. | $19.15 | 2023 | Tyrvaya |
| Dompe US, INC. | $18.27 | 2024 | Oxervate |
| Iridex Corporation | $14.32 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Dunham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.